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Background: The primary colorectal cancer screening test in England is a guaiac faecal occult blood test (gFOBt). The NHS Bowel
Cancer Screening Programme (BCSP) interprets tests on six samples on up to three test kits to determine a definitive positive or
negative result. However, the test algorithm fails to achieve a definitive result for a significant number of participants because they
do not comply with the programme requirements. This study identifies factors associated with failed compliance and
modifications to the screening algorithm that will improve the clinical effectiveness of the screening programme.
Methods: The BCSP Southern Hub data for screening episodes started in 2006–2012 were analysed for participants aged 60–69
years. The variables included age, sex, level of deprivation, gFOBt results and clinical outcome.
Results: The data set included 1 409 335 screening episodes; 95.08% of participants had a definitively normal result on kit 1 (no
positive spots). Among participants asked to complete a second or third gFOBt, 5.10% and 4.65%, respectively, failed to return a
valid kit. Among participants referred for follow up, 13.80% did not comply. Older age was associated with compliance at repeat
testing, but non-compliance at follow up. Increasing levels of deprivation were associated with non-compliance at repeat testing
and follow up. Modelling a reduction in the threshold for immediate referral led to a small increase in completion of the screening
pathway.
Conclusions: Reducing the number of positive spots required on the first gFOBt kit for referral for follow-up and targeted
measures to improve compliance with follow-up may improve completion of the screening pathway.
Bowel cancer screening and compliance. Colorectal cancer
(CRC) is a common form of cancer, with high mortality
(Cancer Research UK, 2013). Colorectal cancer is the second most
common cause of cancer-related mortality in a number of
countries, including the United Kingdom, USA, Japan, Australia,
Canada and Germany (Honein-AbouHaidar et al, 2014). Several
randomised controlled trials (RCTs) have demonstrated a reduc-
tion in CRC mortality with screening (Mandel et al, 1993;
Kewenter et al, 1994; Kronborg et al, 1996; Hardcastle et al,
1996)—whereas CRC-related mortality was reduced by 16% among
people offered guaiac faecal occult blood test (gFOBt) screening, it
was reduced by 25% among people who attended at least one
round of screening (Hewitson et al, 2008), demonstrating the
importance of uptake.
Many studies have investigated the factors associated with
CRC screening uptake, along with the barriers to screening
(Brouse et al, 2003; Beydoun and Beydoun, 2008; Robb et al, 2008;
von Wagner et al, 2009; Von Wagner et al, 2009; Weller and
Campbell, 2009; Pornet et al, 2010; Aubin-Auger et al, 2011; Moss
et al, 2012; Honein-AbouHaidar et al, 2014; Sicsic and Franc, 2014;
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Smith et al, 2014) but there has been little research into the factors
that are associated with completion of a screening episode among
participants who return a first gFOBt. Compliance with a screening
test result has an important impact on clinical outcomes
(Gupta, 2008).
Bowel cancer screening in England. The National Health Service
(NHS) Bowel Cancer Screening Programme (BCSP) was intro-
duced in England in July 2006 after evaluation of a pilot study in
England and Scotland (UK Colorectal Cancer Screening Pilot
Group, 2004). The BCSP achieved a nationwide coverage for 60- to
69-year olds in 2010 (NHS Bowel Cancer Screening Programme,
2011) and for 60- to 74-year olds in 2015 (Bowel Cancer Screening
Southern Programme Hub, 2015). The BCSP currently offers
biennial screening with the gFOBt to all eligible people.
Uptake of screening, defined as the proportion of invited subjects
with a normal (negative) or abnormal (positive) gFOBt result,
varies according to age, sex, socioeconomic status and screening
history (Robb et al, 2008; von Wagner et al, 2009; Von Wagner
et al, 2009; Pornet et al, 2010; Moss et al, 2012; Smith et al, 2014;
Lo et al, 2014b). Participants with a definitive abnormal
gFOBt result are invited to a specialist screening practitioner
(SSP) clinic to discuss the test result and the need for further
investigation (usually by colonoscopy). Completion of a screening
episode is defined as achieving a definitive gFOBt result and, for
gFOBt-positive participants, receiving a follow-up clinical
investigation.
The current screening algorithm in England. The algorithm used
by the BSCP to reach a definitive gFOBt result of normal or
abnormal is unique to the programme in England. It is based on an
algorithm developed for the Nottingham RCT (Hardcastle et al,
1996), which had the explicit aim of reducing the number of false
positives (Robinson et al, 1995; Hardcastle et al, 1996). Each gFOBt
kit has three pairs of windows. Two small faecal samples from
three separate stools are applied by the screening participant to
each of the windows in turn, and any of the six windows or ‘spots’
can test positive for the possible presence of blood in the sample
when tested in the laboratory. Participants with a positive spot
count of 5–6 (‘strong positive’) are referred directly to an SSP clinic
for further investigation. On the first completed test kit, a positive
spot count of 1–4 is considered to provide insufficient evidence of a
bowel lesion and is designated an ‘unclear’ result. A participant
with an ‘unclear’ result is asked to complete a second and,
dependent on the outcome of this kit, a third repeat gFOBt kit to
enable the programme to reach a definitive test result. One or more
positive spots on a valid second kit (or on a third valid kit if all
spots were negative on the second kit) provide a ‘weak positive’
definitive test result and the participant is referred for clinical
investigation. The screening algorithm allows for up to three valid
kits within a single screening episode, but the total number of kits
returned may be greater due to kits that are spoilt (completed
incorrectly by the participant) or technical fails (a problem
encountered during laboratory analysis), which do not count as
valid kits. The current referral algorithm for screening with gFOBt
in England is illustrated in Figure 1.
Alternative screening algorithms. Other countries use different
gFOBt referral algorithms. For example, different thresholds for
direct referral may be used (Benson et al, 2012; Altobelli et al,
2014), or a mixture of screening modalities may be employed
(Fraser et al, 2012). Most programmes outside the UK using a
gFOBt refer participants with any positive spots on their first
(and only) valid kit (Benson et al, 2012), which is consistent with
the referral algorithm used in the three (non-English) RCTs of
gFOBt screening (Mandel et al, 1993; Kewenter et al, 1994;
Kronborg et al, 1996).
Study aims. This study had two main aims. The first aim was to
identify the factors that are associated with the completion of a
screening episode. The second aim was to examine the relationship
between the result of each gFOBt kit completed during a screening
episode and completion of the screening episode (to a definitive
gFOBT test result or, for gFOBt-positive participants, to colono-
scopy or other diagnostic test), and to model the possible effects on
completion if the threshold for immediate referral to follow-up
were lowered from five to three or four positive spots for the first
gFOBt kit.
MATERIALS AND METHODS
Data were provided by the BCSP Southern Hub for first screening
episodes that started between October 2006 and October 2012
(inclusive) among 60- to 69-year olds who had returned at least
one valid gFOBt during the study period. The Southern Hub serves
a population of over 14 million people in the south of England
(Bowel Cancer Screening Southern Programme Hub, 2014;
excluding London).
The study was designed to investigate improvements to the
BCSP screening algorithm using anonymised data. The study was
approved by the BCSP Research Committee and Ethical Commit-
tee approval was not required.
The data set included participant age, sex and deprivation score
and comprehensive gFOBt spot results, test completion dates and
clinical outcomes. The Index of Multiple Deprivation (IMD) score
was derived from the participant’s area of residence (overall IMD
2007) (Communities and Neigbourhoods, 2010). The IMD is
measured on a scale of 0 to 100, with larger values denoting areas
with greater deprivation. During the study period, the process of
extension to 70- to 74-year olds was incomplete. Participants aged
70 years and above were therefore excluded from the analysis as
this age group was not representative of the population that was
offered screening.
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Figure 1. Current referral algorithm for screening with gFOBt.
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The result of each gFOBt kit returned during the screening
episode was recorded according to the count of positive spots
(0–6). Participants who return a ‘normal’ first gFOBt (no positive
spots) require no further investigation. Participants with 1–6 positive
spots on the first gFOBt kit have up to four additional steps along
the screening pathway when they could ‘drop-out’ of screening:
1. Failure to return a second valid gFOBt kit (following an unclear
result on the first valid kit).
2. Failure to return a third valid gFOBt kit (following an unclear
result on the first valid kit and a normal valid second kit).
3. Failure to attend the SSP clinic (following an abnormal test
result [strong positive or a weak positive]).
4. Failure to attend for colonoscopy or other diagnostic test
(following attendance at the SSP clinic).
Subjects who return a first gFOBt kit but fail to reach a definitive
test result (1 and 2 drop-out categories as above) will be invited for
screening again in 2 years’ time, if they remain within the screening
age range. Similarly, subjects who fail to attend the SSP clinic or
follow-up investigation (categories 3 and 4 above) will be contacted
by the relevant Screening Centre and subjects who remain non-
compliant will be returned to routine screening and invited again
in 2 years’ time if they remain withinin the screening age range.
Data on compliance with subsequent screening invitations were
not available for this analysis.
Statistical analyses. Data analysis was performed using STATA
version 10 (College Station, TX, USA). Separate logistic regression
models were built to assess the contribution of age, sex and
deprivation to failure to complete screening at each of the four
steps along the pathway after 1–6 positive spots on the first kit.
Each regression model included participants appropriate for the
model; for example, for completion of kit 3, only participants
eligible to complete kit 3 (unclear kit 1 and normal kit 2) were
included. Tests for linearity and interactions were performed.
Further details on the modelling strategy used to derive the final
regression model are provided in the Supplementary Material.
The data observed for completion of screening at each of the
four steps along the screening pathway were used to predict
completion if the threshold for immediate referral to follow-up
were reduced from a positive spot count of 5 to just 4 or 3 positive
spots. The analysis assumed that completion at each step along the
screening pathway was independent of spot positivity (for any kit)
(for example that participants with 5–6 positive spots on kit 1 were
just as likely to complete a screening episode as participants with
1–2 positive spots on kit 1).
RESULTS
The data set included 1 409 471 participants aged 60–69 years who
were invited to be screened for the first time and had returned at
least one valid gFOBt during the study period. One hundred thirty
six screening episodes (0.01% of the full data set) were excluded
because of missing data (details in Supplementary Material).
The final data set used for this study represented 1 409 335
screening episodes.
The majority of participants (95.08%) returned a normal first
gFOBt kit and were returned to routine screening (Table 1). The
following observations were made on the remaining 4.92% of
participants with 1–6 positive spots on the first gFOBt
(n¼ 69 280).
In all, 4139 participants (5.97%) with 1–6 positive spots
on the first gFOBt had either 5 or 6 positive spots and were
referred to follow-up. The remaining 65 141 participants (94.03%)
had a result that was designated unclear (1–4 positive spots), of
whom 94.90% (61 821) completed a second kit. 27.44% (16 964/
61 821) of participants who returned a second gFOBt kit achieved
a definitive test result (1–6 spots on kit 2) and the remaining
44 857 (72.56%) participants returned a normal second gFOBt kit
and were requested to complete a third kit. Of these, 42 770
(95.35%) completed a third gFOBt kit to achieve a definitive
gFOBt result. Overall, 8.30% (5407/65 141) of participants who
had 1 to 4 positive spots on their first gFOBt kit did not complete
the required number of gFOBt kits and therefore failed to
complete screening (1–4 positive spots on kit 1 but failed to
complete kit 2¼ 3320 (5.10%); no positive spots on kit 2 and
failed to complete kit 3¼ 2087 (4.65%)). Almost two-thirds of
participants asked to complete more than one gFOBt kit
completed three kits to achieve a definitive gFOBt result
(42 770/65 141; 65.66%).
Table 2 shows the proportion of participants referred to an
SSP clinic according to the number of positive spots on kit 1. The
majority of participants with 1 or 2 positive spots on the first kit
were not referred (37 446/56 030; 66.83%), whereas the majority
of participants with 3 or 4 positive spots on the first kit were
referred (5,535/9,111; 60.75%). All participants with 5 or 6
positive spots were referred immediately; of these 4139
participants 92.10% attended the SSP clinic appointment, and
80.41% ultimately complied with the follow-up investigation.
Compared with those who were referred immediately, partici-
pants who completed multiple kits before referral (24 119) were
more likely to both attend the SSP clinic appointment (22 969;
95.23%), and comply with the follow-up investigation (21 029;
Table 1. Distribution of positive spot count results
gFOBt Kit 1 gFOBt Kit 2 gFOBt Kit 3
gFOBt-positive
spot count Number % Number % Number %
0 1 340055 95.08 44857 72.56 35615 83.27
1 34 805 2.47 5774 9.34 3282 7.67
2 21 225 1.51 5552 8.98 2487 5.81
3 4700 0.33 2019 3.27 628 1.47
4 4411 0.31 1819 2.94 494 1.16
5 1798 0.13 859 1.39 128 0.30
6 2341 0.17 941 1.52 136 0.32
Total 1 409 335 100 61821 100 42770 100
Abbreviations: gFOBt¼guaiac faecal occult blood test; NHS¼National Health Service. Participants aged between 60 and 69 years who returned at least one gFOBt kit in response to their first
screening invitation from the NHS Bowel Cancer Screening Southern Programme Hub.
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87.17%). The higher levels of observed compliance may be
because participants had already demonstrated a willingness to
comply with the screening pathway by completing multiple
kits. Overall, 86.20% of participants referred for follow-up
(24 357/28 258) attended the SSP clinic appointment and
received a diagnostic test; the remaining 13.80% of participants
failed to complete screening when referred for follow-up after a
positive gFOBt.
Data on rates of non-compliance with SSP and diagnostic tests
for the demographic variables of age, sex and level of deprivation
are provided in the Supplementary Table. There was little variation
in compliance with attendance at SSP, whereas the biggest
variation in compliance with receiving a diagnostic test was
observed for deprivation quintiles, ranging from 92.72% for the
least deprived quintile to 88.69% for the most deprived quintile.
Among participants receiving a diagnostic test, the proportion
with cancer was 19.41% (289/1489) for participants whose gFOBt
kit 1 had 5 positive spots and 25.18% (463/1839) for those with 6
positive spots on kit 1 (Table 2).
A detailed flowchart illustrating the observed numbers of
participants who completed and did not complete their screening
episode is provided in the Supplementary Material.
Factors associated with completion of a screening episode.
Results of the logistic regression models are presented in Table 3.
Separate regression models were built for men and women because
the association between deprivation and attendance at the SSP
clinic appeared to be markedly different (see the Supplementary
Material for more information).
There was a statistically significant association between age and
completion of screening at each of the four steps along the
screening pathway after a first gFOBt kit with 1–6 positive spots.
Older people were more likely to return a repeat test kit, but were
less likely to attend the SSP appointment or the diagnostic
investigations. Women were more likely to complete their first
repeat test kit, but this association was not observed for subsequent
repeat tests or for attending diagnostic investigations. Increasing
levels of deprivation were associated with increased odds of not
returning either a first or second repeat test kit, as well as increased
odds of not attending for a diagnostic investigation. The
association between deprivation and attending the SSP clinic was
less clear.
The goodness of fit of each model, as measured by the area
under the receiver operating characteristic (AUROC) curve, was
modest with values ranging between 0.53 and 0.56.
Possible effect of changing the referral algorithm on completion
of screening. The possible effects of changing the spot positivity
threshold for requesting a repeat gFOBt kit are presented in
Table 4.
The completion rates (under the current algorithm) for persons
asked to complete a second gFOBT kit (94.90%), a third gFOBT kit
(95.35%) and referred for follow-up (86.20%) were used to predict
completion rates for two changes to the algorithm, that is,. referral
with three or four positive spots on kit 1.
A reduction in the threshold for referral to follow-up from five
positive spots to four or three positive spots on the first kit
inevitably would result in fewer requests for repeat testing and a
greater number of people being referred for follow-up. The number
of participants failing to complete screening after a request for a
repeat gFOBt kit would be reduced, although the number of
participants failing to complete screening following referral for
Table 2. Rates of referral and cancer detection by initial gFOBt-positive spot count result
gFOBt kit 1
positive spot
count
Completed
gFOBt kit
Referred to
SSP
Attended SSP
appointment
Received
diagnostic test
Cancer
found
Proportion
referred for follow up,
95% confidence
interval
Proportion with
cancer of those
receiving diagnostic
tests, 95%
confidence interval
1 34805 10 167 9707 8945 442 29.21% 28.74–29.69% 4.94% 4.51–5.41%
2 21225 8417 8012 7344 530 39.66% 39–40.32% 7.22% 6.65–7.83%
3 4700 2794 2669 2431 282 59.45% 58.04–60.84% 11.60% 10.39–12.93%
4 4411 2741 2581 2309 355 62.14% 60.7–63.56% 15.37% 13.96–16.9%
5 1798 1798 1677 1489 289 100% 99.79–100% 19.41% 17.48–21.5%
6 2341 2341 2135 1839 463 100% 99.84–100% 25.18% 23.25–27.21%
Total 69 280 28 258 26 781 24 357 2361 40.79% 40.42–41.15% 9.69% 9.33–10.07%
Abbreviations: gFOBt¼guaiac faecal occult blood test; NHS¼National Health Service. Participants aged between 60 and 69 years who returned at least one gFOBt kit in response to their first
screening invitation from the NHS Bowel Cancer Screening Southern Programme Hub, where the result of kit 1 was 1–6 positive spots.
Table 3. Predictors of completion at different parts of the screening pathway. See text for definitions
Returning kit 2 Returning kit 3
Attending
SSP—Females
Attending
SSP—Males
Attending for
investigations
Number eligible 65 141 44 857 11 491 16 767 26 781
Number not
completing (%)
3320 (5.10) 2087 (4.65) 655 (5.70) 822 (4.90) 2424 (9.05)
Odds ratios
1-year increase in age. 1.013 (1.002 to 1.025) 1.050 (1.035 to 1.065) 0.975 (0.952 to 1.000) 0.970 (0.949 to 0.992) 0.975 (0.962 to 0.988)
Female sex 1.228 (1.143 to 1.319) 1.063 (0.973 to 1.161) N/A N/A 0.972 (0.892 to 1.058)
5-unit increase in IMD
2007 score
0.929 (0.915 to 0.943) 0.937 (0.919 to 0.954) 1.038 (0.998 to 1.078) 0.997 (0.966 to 1.029) 0.923 (0.907 to 0.939)
Constant; beta
coefficient
 2.229 ( 2.938 to  1.520)  0.106 ( 1.009 to 0.798)  4.290 ( 5.875 to 2.705)  4.929 ( 6.349 to 3.509)  4.220 ( 5.066 to  3.374)
AUROC 0.556 (0.546 to 0.566) 0.558 (0.546 to 0.571) 0.539 (0.517 to 0.562) 0.527 (0.506 to 0.547) 0.553 (0.541 to 0.565)
Abbreviations: AUROC¼ area under the receiver operating characteristic; IMD¼ indices of multiple deprivation; SSP¼ specialist screening practitioner. Figures in brackets are 95% confidence
intervals, unless otherwise stated. Confidence intervals for the AUROC were estimated using the roctab command in STATA, assuming asymptotic normality.
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follow-up would increase. The overall increases in participants
referred for diagnostic test were estimated to be 5.80% and 12.49%
for thresholds of four and three positive spots, respectively.
Of the 69 280 participants with a spot count greater than zero on
their first kit (i.e., participants at risk of failing to complete the
screening pathway), overall non-completion (failure to reach a
definitive gFOBt result and failure to attend for follow-up if the
gFOBt result was abnormal) was 13.44% using the current
threshold for immediate referral (5 positive spots on kit 1).
Estimated overall non-completion decreased to 13.31% for
immediate referral with 4 positive spots and to 13.19% with 3
positive spots, which corresponded to an additional 90 or 172
participants completing the screening pathway. The Southern Hub
covers approximately a quarter of the population in England
(Bowel Cancer Screening Southern Programme Hub, 2014), so at a
national level, approximately 360 or 690 additional people would
be expected to complete the screening pathway using referral
thresholds of four or three positive spots, respectively.
CONCLUSIONS AND DISCUSSION
The success of any screening programme depends upon uptake of
screening (proportion of invitees achieving a definitive result) and
compliance with follow-up investigations for participants with
positive primary test results.
We identified four steps in the bowel cancer screening pathway
when participants who have returned a first gFOBt kit with 1–6
positive spots may subsequently fail to complete screening. Among
participants asked to complete a second gFOBt kit, 5.10%
subsequently failed to complete screening, and 4.65% of those
asked to complete a third gFOBt failed to do so. Among
participants who achieved a definitive gFOBt test result and were
referred, 13.80% failed to attend the SSP clinic or a follow-up
diagnostic test. Participants with five or six positive spots on kit 1
are more likely to have cancer but only 80.41% complied with the
follow-up investigation. Although some participants may have
sought private medical healthcare outside the BCSP, reducing non-
completion (failure to comply with follow-up) in this group should
be a priority.
In this data set, 9308 (13.44%) participants overall returned an
initial (valid) gFOBt kit with a non-zero spot count but failed to
complete the bowel cancer screening pathway. Cancer was
identified in 3.41% (2361/69 280) of all participants with 1–6
positive spots on kit 1 and among 9.69% (2361/24 357) of all
participants who were referred for follow-up and underwent a
diagnostic investigation. This suggests that among the population
covered by the Southern Hub and during the six-year study period
(October 2006 to October 2012), the number of cancers among
participants who failed to complete the screening pathway may
have ranged between 317 and 902, assuming that the prevalence of
cancer among drop-outs ranged between 3.41 and 9.69%. As the
Southern Hub covers approximately a quarter of the population in
England (Bowel Cancer Screening Southern Programme Hub,
2014) and assuming that the rates of non-completion observed in
this study are representative of rates nationally, the corresponding
number of cancers diagnosed in England could be between 1250
and 3600 over the 6-year period in 60- to 69-year olds screened for
the first time. The results of this study suggest that lower
thresholds for referral would mean that more participants
complete the screening pathway, which will result in more cancers
being detected. In addition, lower thresholds would result in more
positive results among people who return a first test kit. For a
threshold of four (or three) spots positive, this would be people
who, under the current screening programme, have four (or three)
spots positive on their first kit, followed by no positive spots on kits
two and three. These additional positive results would lead to an
increase in sensitivity (as there will be more true positive test
results), but also a decrease in specificity (as there will be more false
positive test results). As estimate of these changes in test
characteristics cannot be quantified with the existing data.
Increasing age and having lower levels of deprivation were
associated with increased odds for completing a second or third
gFOBt kit. Older age and greater deprivation were associated with a
significantly decreased odds of attending diagnostic investigations.
The association between non-completion of a screening episode,
age, sex and deprivation has been studied before (Pornet et al,
2010; Birkenfeld et al, 2011), and the association between poorer
uptake and increasing levels of deprivation is well documented
(Von Wagner et al, 2009; Birkenfeld et al, 2011; von Wagner et al,
2011). Further, there is some evidence that the requirement to
repeat gFOBt kits to reach a definitive test result and failure to
attend for follow up is associated with reduced participation in
subsequent screening episodes (Lo et al, 2014a; Lo et al, 2014b).
However, to the best of our knowledge, this is the first study to
examine non-completion at different steps along the screening
pathway after returning at least one gFOBt. This is also the first
study to explicitly consider potential non-linearity and interactions
among the associations between patient demographics and non-
completion of a screening episode.
There are several limitations to this work. The data set was
derived from regional data from the BCSP Southern Hub. The
South of England has lower levels of deprivation than the rest of
Table 4. Non-completion at different steps in the screening pathway: observed rates for current BCSP and predicted rates under
different thresholds for referral
Threshold for referral at gFOBt kit 1
5a (current BCSP) 4b (predicted) 3b (predicted)
Requested to complete a second gFOBt 65 141 60 730 56030
Non-completion of second gFOBt (% of requests) 3320 (5.10%) 3095 (5.10%) 2856 (5.10%)
Requested to complete a third gFOBt 44 857 42 894 40670
Non-completion of third gFOBt (% of requests) 2087 (4.65%) 1996 (4.65%) 1892 (4.65%)
Referred for follow-up 28 258 29 898 31786
Non-completion of referral (% of those referred) 3901 (13.80%) 4127 (13.80%) 4388 (13.80%)
Non-completion (at repeat gFOBt or referral) 9308 9218 9136
Percentage of those with a kit 1 spot count 40 (n¼69 280) 13.44% 13.31% 13.19%
Abbreviations: gFOBt¼guaiac faecal occult blood test; NHS¼National Health Service.
aFor threshold of 5 (current BCSP threshold) values are based on the observed data.
bFor thresholds of 3 and 4 values presented are predictions, assuming non-completion rates of 5.10%, 4.65% and 13.80% for second gFOBt, third gFOBt and follow-up, respectively.
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England (Logan et al, 2012), which may limit the generalisability of
the results, although the effect of deprivation was included in the
statistical modelling. As an association between levels of depriva-
tion and non-compliance has been demonstrated in this study, the
modelled effects of reducing the threshold for referral are likely to
be conservative. In addition, only three patient demographics (age,
sex and deprivation levels) were available for analyses, and there is
a range of other factors that may affect compliance (Honein-
AbouHaidar et al, 2014), such as ethnicity (Robb et al, 2008),
literacy levels (von Wagner et al, 2009), the presence of certain co-
morbidities (Heslop et al, 2013) and screening history (Lo et al,
2014a; Lo et al, 2014b). The small number of patient demographics
available is likely to be reflected by the relatively low AUROC
values (between 0.53 and 0.56) for each of the models. Further, the
measure of deprivation employed for this study is area based and
so will not be as accurate as individual-based measures of
deprivation due to potential heterogeneity in deprivation within
an area. The regression results reported here should be interpreted
with caution. The true disease status (whether or not a participant
has cancer) is not known for all participants. Hence, the impact of
a change in the threshold for referral on the number of false-
positive and false-negative test results is unknown. This is likely to
be an important consideration for decision makers when
considering changes to the threshold, particularly as the impact
on numbers completing is modest. Any algorithm changes would
also have other changes that are not captured in this analysis. This
includes the additional resources and costs required for additional
colonoscopies, and the potential impact on participants’ quality of
life. The assumption that completion of a screening episode is not
dependent upon the number of spots positive on any gFOBt kit
and that the data observed for the current algorithm can be used to
predict completion of a screening episode if the referral were
changed, requires further investigation. The restriction to first
screening episodes may also limit the generalisability of the
findings to current screening programmes. However, uptake rates
are much higher for subsequent screens than for initial screens
(Kearns et al, 2014), which suggest that attempts to improve
completion should focus on initial screening episodes. A final
important limitation to note is that not all of the participants who
fail to complete the screening pathway will do so for reasons that
are amenable to intervention. For example, participants may leave
the pathway for clinical reasons, or may choose to change to a
private healthcare provider. These reasons are most likely to occur
for participants who fail to attend for further diagnostic
investigations, and may explain why rates of non-completion are
highest at this step in the screening pathway. Hence, the non-
completion rates reported here could be overestimated.
Within the BCSP, once-only screening with flexible sigmoido-
scopy at age 55 years is being introduced in addition to screening
with gFOBt for 60- to 74-year olds (Geurts et al, 2015), whereas the
use of faecal immunochemical testing for haemoglobin (FIT)
instead of the gFOBT has been piloted in the south of England
(Bowel Cancer Screening Southern Programme Hub, 2015; Moss
et al, 2015). These changes may have an impact on the completion
of screening episodes. However, in order to assess the effectiveness
of these changes, comparisons shall be required with the existing
evidence about the sociodemographic factors that are associated
with drop-out, and how these vary across the current screening
programme. In addition, many other countries use gFOBt screen-
ing (Benson et al, 2012), and so the results presented here will be of
interest beyond the BCSP.
As with interventions to increase screening uptake (Shankaran
et al, 2007), targeted interventions may be required to help tackle
potential health inequalities (Asaria et al, 2014). On the basis of the
results of this study, and noting the previously mentioned
limitations, it is recommended that measures to improve
completion should be targeted at participants who are referred
for further investigations, with particular emphasis on older
participants and those from more deprived areas. As an increasing
level of deprivation is associated with a reduction in both uptake
and completion, any interventions aimed at improving uptake
among these areas may also have a beneficial effect on compliance.
Further research eliciting the reasons for non-completion at each
part of the screening pathway would also be beneficial.
Changing the spot positivity threshold for repeating gFOBt is
likely to have several effects (Geraghty et al, 2014). There would be
a reduction in the number of participants being asked to provide
more than one gFOBt kit and an increase in endoscopy
requirements due to an increased number of referrals. Such a
change is likely to improve completion at repeat testing but
decrease completion at referral. The combination of these two
effects may improve overall completion of screening episodes,
although the effect is likely to be small. Larger variations in uptake
were observed by deprivation quintile, which may require more
urgent attention.
Failure by participants to complete the bowel cancer screening
pathway will result in some cancers not being identified. Targeted
measures to improve completion of the screening pathway, with a
particular emphasis on participants who are referred for follow-up
and more deprived groups, could help to improve outcomes within
the BCSP.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Altobelli E, Lattanzi A, Paduano R, Varassi G, di Orio F (2014) Colorectal
cancer prevention in Europe: burden of disease and status of screening
programs. Prev Med 62: 132–141.
Asaria M, Griffin S, Cookson R, Whyte S, Tappenden P (2014)
Distributional Cost-Effectiveness Analysis of Health Care Programmes—
A Methodological Case Study of the UK Bowel Cancer Screening
Programme. Health Econ 24(6): 742–754.
Aubin-Auger I, Mercier A, Lebeau JP, Baumann L, Peremans L, Van Royen P
(2011) Obstacles to colorectal screening in general practice: a qualitative
study of GPs and patients. Fam Pract 28(6): 670–676.
Benson VS, Atkin WS, Green J, Nadel MR, Patnick J, Smith RA, Villain P
(2012) Toward standardizing and reporting colorectal cancer screening
indicators on an international level: the International Colorectal Cancer
Screening Network. Int J Cancer 130(12): 2961–2973.
Beydoun HA, Beydoun MA (2008) Predictors of colorectal cancer screening
behaviors among average-risk older adults in the United States. Cancer
Causes Control 19(4): 339–359.
Birkenfeld S, Belfer RG, Chared M, Vilkin A, Barchana M, Lifshitz I,
Fruchter D, Aronski D, Balicer R, Niv Y (2011) Factors affecting
compliance in faecal occult blood testing: a cluster randomized study of
the faecal immunochemical test versus the guaiac faecal occult test.
J Med Screen 18(3): 135–141.
Bowel Cancer Screening Southern Programme Hub (2014) Bowel Cancer
Screening Southern Programme Hub—Summary report: 2012–2013.
Available at http://royalsurrey.staging.flipsidegroup.com/bowel-cancer-
screening-southern-hub (accessed 28 December 2015).
Bowel Cancer Screening Southern Programme Hub (2015) Bowel Cancer
Screening Southern Programme Hub—Summary report: 2013–2014.
Available at http://royalsurrey.staging.flipsidegroup.com/bowel-cancer-
screening-southern-hub (accessed 28 December 2015).
Brouse CH, Basch CE, Wolf RL, Shmukler C, Neugut AI, Shea S (2003)
Barriers to colorectal cancer screening with fecal occult blood testing in a
predominantly minority urban population: a qualitative study. Am J Public
Health 93(8): 1268–1271.
Cancer Research UK (2013) Cancer Statistics: Key Facts: Bowel Cancer
April 2013.
BRITISH JOURNAL OF CANCER Completion of bowel cancer screening
332 www.bjcancer.com |DOI:10.1038/bjc.2015.469
Communities and Neigbourhoods (2010) Indices of Deprivation 2007.
Department for Communities and Local Government.
Fraser CG, Digby J, McDonald PJ, Strachan JA, Carey FA, Steele RJ (2012)
Experience with a two-tier reflex gFOBT/FIT strategy in a national bowel
screening programme. J Med Screen 19(1): 8–13.
Geraghty J, Butler P, Seaman H, Snowball J, Sarkar S, Blanks R, Halloran S,
Bodger K, Rees C (2014) Optimising faecal occult blood screening:
retrospective analysis of NHS Bowel Cancer Screening data to improve the
screening algorithm. Br J Cancer 111(11): 2156–2162.
Geurts SME, Massat NJ, Duffy SW (2015) Likely effect of adding flexible
sigmoidoscopy to the English NHS Bowel Cancer Screening Programme:
impact on colorectal cancer cases and deaths. Br J Cancer 113(1): 142–149.
Gupta S (2008) Will test-specific adherence predict the best colorectal cancer
screening strategy? Ann Intern Med 149(9): 659–669.
Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS,
Balfour TW, James PD, Mangham CM (1996) Randomised controlled trial
of faecal-occult-blood screening for colorectal cancer. Lancet 348(9040):
1472–1477.
Heslop P, Blair P, Fleming P, Hoghton M, Marriott A, Russ L (2013)
Confidential inquiry into premature deaths of people with learning
disabilities (CIPOLD): final report. Available at www.bristol.ac.uk/cipold/
fullfinalreport.pdf (accessed 28 December 2015).
Hewitson P, Glasziou P, Watson E, Towler B, Irwig L (2008) Cochrane
systematic review of colorectal cancer screening using the fecal occult
blood test (hemoccult): an update. Am J Gastroenterol 103(6): 1541–1549.
Honein-AbouHaidar GN, Kastner M, Vuong V, Perrier L, Rabeneck L,
Tinmouth J, Straus S, Baxter NN (2014) Benefits and barriers to
participation in colorectal cancer screening: a protocol for a systematic
review and synthesis of qualitative studies. BMJ Open 4(2): e004508.
Kearns B, Whyte S, Chilcott J, Patnick J (2014) Guaiac faecal occult blood test
performance at initial and repeat screens in the English Bowel Cancer
Screening Programme. Br J Cancer 111(9): 1734–1741.
Kewenter J, Brevinge H, Engaras B, Haglind E, Ahran C (1994) Results of
screening, rescreening, and follow-up in a prospective randomized study
for detection of colorectal cancer by fecal occult blood testing: results for
68,308 subjects. Scand J Gastroenterol 29(5): 468–473.
Kronborg O, Fenger C, Olsen JA, Jargensen OD, Sandergaard O (1996)
Randomised study of screening for colorectal cancer with faecal-occult-
blood test. Lancet 348(9040): 1467–1471.
Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, Von Wagner C (2014a)
Predictors of repeat participation in the NHS bowel cancer screening
programme. Br J Cancer 112(1): 199–206.
Lo SH, Halloran S, Snowball J, Seaman H, Wardle J, von Wagner C (2014b)
Colorectal cancer screening uptake over three biennial invitation rounds
in the English bowel cancer screening programme. Gut 64(2): 282–291.
Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C
(2012) Outcomes of the Bowel Cancer Screening Programme (BCSP) in
England after the first 1 million tests. Gut 61(10): 1439–1446.
Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM,
Ederer F (1993) Reducing mortality from colorectal cancer by screening
for fecal occult blood. N Engl J Med 328(19): 1365–1371.
Moss S, Mathews C, Day T, Smith S, Halloran SP (2015) OC-002
Increased participation in colorectal cancer screening during a pilot of
faecal immunochemical test for haemoglobin (FIT) in england. Gut
64(Suppl 1): A1.
Moss SM, Campbell C, Melia J, Coleman D, Smith S, Parker R, Ramsell P,
Patnick J, Weller DP (2012) Performance measures in three rounds of the
English bowel cancer screening pilot. Gut 61(1): 101–107.
NHS Bowel Cancer Screening Programme (2011) In the loop newsletter for
people working in the NHS Bowel Cancer Screening Programme, Winter
2010/2011, pp 1–4.
Pornet C, Dejardin O, Morlais F, Bouvier VA˜, Launoy G (2010)
Socioeconomic determinants for compliance to colorectal cancer
screening. A multilevel analysis. J Epidemiol Community Health 64(4):
318–324.
Robb KA, Power E, Atkin W, Wardle J (2008) Ethnic differences in
participation in flexible sigmoidoscopy screening in the UK. J Med Screen
15(3): 130–136.
Robinson MHE, Moss SM, Hardcastle JD, Whynes DK, Chamberlain JO,
Mangham CM (1995) Effect of retesting with dietary restriction
in Haemoccult screening for colorectal cancer. J Med Screen 2(1):
41–44.
Shankaran V, McKoy JM, Dandade N, Nonzee N, Tigue CA, Bennett CL,
Denberg TD (2007) Costs and cost-effectiveness of a low-intensity patient-
directed intervention to promote colorectal cancer screening. J Clin Oncol
25(33): 5248–5253.
Sicsic J, Franc C (2014) Obstacles to the uptake of breast, cervical, and
colorectal cancer screenings: what remains to be achieved by French
national programmes? BMC Health Serv Res 14(1): 465.
Smith SK, Simpson JM, Trevena LJ, McCaffery KJ (2014) Factors associated
with informed decisions and participation in bowel cancer screening
among adults with lower education and literacy. Med Decis Making 34(6):
756–772.
UK Colorectal Cancer Screening Pilot Group (2004) Results of the first round
of a demonstration pilot of screening for colorectal cancer in the United
Kingdom. BMJ 329(7458): 133.
Von Wagner C, Good A, Wright D, Rachet B, Obichere A, Bloom S, Wardle J
(2009) Inequalities in colorectal cancer screening participation in the first
round of the national screening programme in England. Br J Cancer 101:
S60–S63.
von Wagner C, Baio G, Raine R, Snowball J, Morris S, Atkin W, Obichere A,
Handley G, Logan RF, Rainbow S (2011) Inequalities in participation in an
organized national colorectal cancer screening programme: results from
the first 2.6 million invitations in England. Int J Epidemiol 40(3): 712–718.
von Wagner C, Semmler C, Good A, Wardle J (2009) Health literacy and
self-efficacy for participating in colorectal cancer screening: the role of
information processing. Patient Educ Couns 75(3): 352–357.
Weller DP, Campbell C (2009) Uptake in cancer screening programmes:
a priority in cancer control. Br J Cancer 101: S55–S59.
This work is published under the standard license to publish agree-
ment. After 12 months the work will become freely available and
the license terms will switch to a Creative Commons Attribution-
NonCommercial-Share Alike 4.0 Unported License.
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
Completion of bowel cancer screening BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2015.469 333
